Prelude Capital Management’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-212,323
| Closed | -$11.1M | – | 2295 |
|
|
2020
Q3 | $11.1M | Buy |
212,323
+196,179
| +1,215% | +$8.12M | 0.54% | 27 |
|
|
2020
Q2 | $537K | Buy |
16,144
+8,791
| +120% | +$280K | 0.03% | 459 |
|
|
2020
Q1 | $200K | Buy |
+7,353
| New | +$205K | 0.01% | 449 |
|
|
2017
Q2 | – | Sell |
-7,369
| Closed | -$98K | – | 1974 |
|
|
2017
Q1 | $98K | Buy |
+7,369
| New | +$115K | 0.01% | 789 |
|
|
2016
Q4 | – | Sell |
-20,117
| Closed | -$235K | – | 1893 |
|
|
2016
Q3 | $235K | Buy |
+20,117
| New | +$237K | 0.02% | 517 |
|
|
2016
Q2 | – | Sell |
-5,402
| Closed | -$50K | – | 1819 |
|
|
2016
Q1 | $50K | Buy |
5,402
+1,602
| +42% | +$17.2K | 0.01% | 977 |
|
|
2015
Q4 | $56K | Buy |
+3,800
| New | +$63.6K | 0.01% | 1019 |
|
|
2014
Q4 | – | Sell |
-4,300
| Closed | -$49K | – | 2252 |
|
|
2014
Q3 | $49K | Sell |
4,300
-4,200
| -49% | -$47.9K | 0.01% | 1396 |
|
|
2014
Q2 | $103K | Buy |
8,500
+6,500
| +325% | +$76.8K | 0.01% | 1089 |
|
|
2014
Q1 | $23K | Sell |
2,000
-4,069
| -67% | -$68.9K | ﹤0.01% | 1650 |
|
|
2013
Q4 | $107K | Hold |
6,069
| – | – | 0.02% | 834 |
|
|
2013
Q3 | $87K | Sell |
6,069
-9,163
| -60% | -$140K | 0.01% | 818 |
|
|
2013
Q2 | $229K | Buy |
+15,232
| New | +$201K | 0.05% | 419 |
|
Prelude Capital Management's MNTA Position: Q4 2020 in Review
Prelude Capital Management sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q4 2020, closing a stake of 212,323 shares — an estimated $11.1M sold.
Prelude Capital Management first reported a position in MNTA in Q2 2013 and held it in 13 quarters. The position peaked at $11.1M in Q3 2020. 0 funds tracked by Wall St. Rank hold MNTA as of Q4 2020.
- Prelude Capital Management reported no remaining Momenta Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
- Prelude Capital Management sold 212,323 Momenta Pharmaceuticals, Inc. shares in Q4 2020, an estimated $11.1M.
- Prelude Capital Management first reported a position in Momenta Pharmaceuticals, Inc. in Q2 2013 and held it in 13 quarters.
- Prelude Capital Management's Momenta Pharmaceuticals, Inc. position peaked at $11.1M in Q3 2020.
- 0 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q4 2020.
Based on Prelude Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.